Daehan New Pharm Co., Ltd. Overview
Daehan Nupharm is a Korean mid-sized (중견) specialty pharmaceutical manufacturer. It began in 1984 as an animal-drug and feed-additive maker and has since expanded into human prescription drugs, non-reimbursed "well-being" injectables, oral anti-obesity drugs, animal health, bioprocess media and health functional foods. Revenue has held at about KRW 200bn for four years (FY2025: KRW 202.4bn). The mix in Q1 2026 was human pharmaceuticals 56%, animal health 26%, exports 8% and contract manufacturing/other 10%. The company's differentiating assets are a long-standing injectable franchise (glutathione "Luchion", lyophilized "Liporase"), a well-known appetite-suppressant portfolio, and a dual human/veterinary GMP base in the Hyangnam pharmaceutical complex. That base has just been expanded by a roughly KRW 81bn EU-GMP Annex 1-oriented plant targeting commercial operation in early 2027. The investment case now depends on whether that capacity converts into growth. Against it stand compressed margins, rising CSO commissions, net debt of about KRW 90bn, and a succession process that is still incomplete.
The company's own description
On its website, Daehan Nupharm describes a lineage running "from care to cure." It says it started with animal medicines in 1984 and extended into human medicines, biologics and health functional foods, building on long experience in protecting life and health (company product overview page, 2026). It frames its identity around three core values: People, Principle and Challenge. Its "Core Strategy" has four pillars: talent development, stronger R&D capability, cross-divisional business synergy, and sustainable profitable growth across all businesses (company vision page).
The FY2025 business report classifies the business into four reporting lines:
-
Human pharmaceuticals (인체의약품)
-
Animal pharmaceuticals (동물의약품)
-
Overseas business division (해외사업부)
-
Contract manufacturing and other (수탁·기타)
WISEreport's June 2026 company summary describes the prescription portfolio as concentrated in metabolic diseases and peptic ulcer, with R&D extending into obesity and into dementia and Parkinson's disease (WISEreport company overview, as of 1 June 2026).
Business model and revenue model
| Dimension | Characterization | Evidence |
|---|---|---|
| Revenue model | Almost entirely product sales (own-manufactured plus in-licensed or distributed products). Contract manufacturing and other income is about 7% to 10% of revenue. No subscription or meaningful licensing income is disclosed | Segment mix (Dailypharm, 10 Jul 2026; butler.works Q2 2026) |
| Product vs. service | Product-based. Services are limited to contract manufacturing (수탁) | Same |
| Manufacturing model | Vertically integrated manufacturer of oral solids, injectables (including lyophilized vials and ampoules) and veterinary dosage forms at the Hyangnam complex. It supplements its own line with in-licensed and distributed products | Factory page; history page |
| Human Rx channel | Hospitals and clinics through the in-house sales force and, increasingly, contract sales organizations (CSOs). Commissions paid (지급수수료) grew from KRW 20.6bn in FY2022 to KRW 26.9bn (FY2023) and KRW 37.5bn (FY2024), then passed KRW 40bn for the first time in FY2025 | Dealsite, 21 Aug 2025; Dailypharm, 10 Jul 2026 |
| Self-pay (non-reimbursed) channel | Clinics using "well-being" injectables (glutathione, vitamins, SAMe, thymosin and similar) and aesthetic products | Company and press (2018–2026) |
| OTC and health functional foods | Pharmacies (for example, the DiNU Kiup product is supplied to about 22,000 pharmacies), online (DiNU store, Naver live commerce), TV home shopping (CJ Onstyle), and a clinic-exclusive line (Dr. DiNU) | Company news, 2025–2026 |
| Animal health channel | Livestock farms, distributors and veterinary hospitals (veterinarian-only mall "diange"), plus government procurement (30 products listed for 관납, i.e., public supply) | Company product catalog |
| Export channel | Distributors and registrations in Southeast Asia, Latin America, the Middle East, Russia/CIS and Central Asia | Medigate News, 12 May 2022; company news, 7 May 2026 |
| Value-chain position | Mid-stream: formulation, manufacturing and marketing of mostly generic, improved-generic and in-licensed products. It is not a discovery-stage innovator, and active ingredients are largely sourced externally | Product catalog; pipeline page |
Customer types and end-markets
| End-market | Customers | Representative products |
|---|---|---|
| Prescription (reimbursed) | Clinics, hospitals and long-term care facilities | Cardiovascular (44 SKUs), gastrointestinal (21), endocrine/diabetes (18) products; Rapiduo, Newtozet, NP Dapa, Dapaformin |
| Obesity (mostly self-pay oral) | Obesity and primary-care clinics | Pentin (phendimetrazine), Festin and PTM (phentermine), Migbos (miglitol), Campbell Double |
| Self-pay injectables and aesthetics | Aesthetic, pain, integrative-oncology and wellness clinics | Luchion inj (glutathione), Liporase inj, NuPN inj, V-Bella inj, Derma Cindella (device) |
| Livestock and aquaculture | Cattle, swine, poultry, fish and bee farms; distributors; government procurement | Granmectin (ivermectin), Neovitarincal, Cowmix, Super Cow, Neoflo, feed supplements |
| Companion animals | Veterinary hospitals | DH Fuzol tab, Qvecin inj, D'ange brand |
| Bioprocess | Cell-culture and biomanufacturing laboratories | CELRENA, BMPro, BMPro-V, ALyS505NK-EX serum-free media |
| Consumers | Pharmacies, e-commerce, home shopping | DiNU (probiotics, propolis, vitamin C, melatonin, children's growth supplement), Harker Herbals |
| Export | Overseas distributors | Liporase (lyophilized), Luchion inj, Tambutin tab (historical Russia top-3 listing) |
Independent characterization
Daehan Nupharm is best understood as a portfolio of domestic niches, not an R&D-driven pharmaceutical company. Its economic engine has three parts:
-
a self-pay injectable franchise that historically delivered gross margins above 50%;
-
an oral obesity franchise built on older appetite suppressants; and
-
a steady animal-health business that gives counter-cyclical diversification.
The weak spot is the reimbursed generic portfolio. With no distinctive lead product, the company has increasingly relied on CSOs and rising commission rates to win prescriptions. This explains why gross margin fell from 55.7% (FY2016) to 45.6% (FY2025) and why operating margin fell from 16.5% (FY2020) to 5.8% (FY2025).
Two unusual features stand out for a company of its size:
Capital allocation into non-core assets: These include a 10.8% stake in Caspian Sunrise, a Kazakhstan oil and gas company that grew out of a 2007 oil-field investment, and a listed-equity portfolio of SK hynix, Nvidia, Broadcom, Apple, Microsoft, Samsung Biologics, QQQ and SLV positions.
- Owner-family control (40.5%) combined with a low free-float valuation.
Strategy
Stated strategy themes (company website and management statements, 2023–2026; paraphrased)
-
Capacity-led growth (Hyangnam Project 1-2-3). Phase 1 was the research building (2023). Phase 2 is the GMP Plant 2 (2025, about KRW 81bn). Phase 3 is an automated warehouse. Management says the plant provides a base for stable supply of high-quality medicines and for export expansion, and has said it will strengthen the sales organization to convert higher output and new products into sales from 2027 (Newspim, 14 May 2026).
-
R&D upgrade. The pipeline centers on improved new drugs: obesity, hypertension, GERD, hyperlipidemia and central nervous system. The bio research institute works on cell therapy and anti-aging. New R&D leadership was hired in 2025.
-
Therapeutic-area focus. Metabolic disease (diabetes, dyslipidemia, obesity), gastrointestinal, and expansion into dementia and Parkinson's disease (WISEreport, June 2026).
-
Divisional synergy. A Future Business Division was created in 2023 to link the human, animal and HFF units (Medigate News, 4 Jan 2023).
-
Companion-animal growth. D'ange brand, veterinarian-only mall, DH Fuzol, Qvecin, and the Nustem cell-therapy pipeline.
-
Consumer health. DiNU brand expansion through e-commerce, live commerce, home shopping, pharmacy distribution and a licensed character edition.
-
Export diversification. Central Asia/CIS, building on Southeast Asian, Middle Eastern and Latin American registrations.
-
Governance and ESG. An anti-bribery management system (annual board review since 2022), a fair-trade compliance program (disclosures in Jan and Jul 2026), and a KITA ESG A- rating.
Strategic initiatives announced or executed in the last 24 months (Oct 2024 to Oct 2026)
| Initiative | Date | Details | Status |
|---|---|---|---|
| 4-week obesity injectable consortium | Dec 2024 | Joint development with Daewoong, Tionlab Therapeutics and Darim Biotech, covering non-clinical work through approval | Preclinical (consortium-level); Daehan's specific role and economics not disclosed |
| Overseas equity investment | 5 Mar 2025 (board approval) | Target and amount not disclosed | Executed (per board record) |
| R&D leadership reinforcement | H1 2025 | Gil Young-sik and Park Jung-tae hired | Done |
| Plant 2 completion | Aug 2025 | About KRW 81bn; 1bn+ dosage units of solid-dose capacity | Validation and product transfer under way; GMP approval target Aug–Nov 2026 |
| Additional capex | 2025–2027 | KRW 15bn for production capacity and buildings, KRW 4.5bn for maintenance (IB Tomato) | Planned |
| DiNU line extensions | Dec 2025 to Apr 2026 | Melatonin, kale, oral probiotics, Kiup Pokémon edition | Launched |
| New distributed brand | Apr 2026 | Harker Herbals (New Zealand) | Launched |
| Central Asia push | Apr 2026 | Tashkent medical expo; Uzbek registrations | Ongoing |
| Companion-animal antibiotic | Jul 2026 | Qvecin inj (cefovecin) | Launched |
| Sales-force reinforcement | 2,026 | Expanding the sales organization ahead of 2027 output | Ongoing |
Cost programs and medium-term targets
No formal cost-reduction program with quantified targets is disclosed. No medium-term financial guidance (revenue, margin or ROE targets) is publicly disclosed. In 2021 the company referred to a "3-year target" and broad hiring but did not publish numbers (iNews24, 2021). Management's operational targets are:
-
GMP approval of Plant 2 in Aug–Nov 2026;
-
start of the injectable line in early 2027 (January 2027 was the original target); and
-
solid-dose capacity about double FY2024 production for each dosage form (IB Tomato, 3 Sep 2025).
Products & Services
The company's online catalog (October 2026) lists 208 human-medicine SKUs: 154 oral, 43 injectable, 11 other, including 15 flagged as new. It also lists 183 veterinary SKUs: 50 cattle, 48 swine, 18 poultry, 21 aquaculture, 4 apiculture, 12 companion-animal and 30 government-procurement items. Pricing for individual products is not publicly disclosed; reimbursed products follow Korea's national health insurance price list. The tables below cover flagship and recently launched products product by product. Launch years are given where disclosed.
Human pharmaceuticals — prescription and self-pay
| Product | Composition / description | Therapeutic use | Target customer | Launch / latest | Source |
|---|---|---|---|---|---|
| Rapiduo tab 10/350 mg | Rabeprazole (PPI) plus magnesium oxide (antacid). Improved new drug; the company describes it as the first such combination, reaching peak blood levels within about one hour | Gastroesophageal reflux disease (GERD) | GI and primary-care clinics | Dec 2023 / Mar 2024 | Company history; Smart Today, 16 May 2024 |
| Newtozet | Dyslipidemia fixed-dose combination (exact molecules not specified in sources) | Dyslipidemia | Clinics | 2,021 | iNews24 (2021) |
| Newtomega soft capsule | Atorvastatin plus omega-3 acid ethyl esters | Dyslipidemia / hypertriglyceridemia | Clinics | Jun 2023 (planned) | Medigate News, 12 May 2023 |
| Migbos FC tab | Miglitol; carbohydrate-absorption inhibitor sold under domestic exclusive rights | Diabetes / post-meal glucose control (also used in obesity practice) | Clinics | 2,021 | iNews24 (2021); Dealsite, 21 Aug 2025 |
| NP Dapa tab 10 mg | Dapagliflozin generic | Type 2 diabetes | Clinics | — | Company catalog |
| Dapaformin XR tab 10/500 and 10/1000 mg | Dapagliflozin plus metformin extended-release | Type 2 diabetes | Clinics | — | Company catalog |
| Campbell Double tab | Bangpungtongseong-san herbal preparation (CSO commission raised from 45% to 55% in March 2025) | Obesity-adjacent / constipation (herbal) | Clinics | — | Dealsite, 21 Aug 2025 |
| Pentin | Phendimetrazine appetite suppressant | Obesity | Obesity clinics | Long-standing | Dealsite, 21 Jul 2017 |
| Festin | Phentermine appetite suppressant | Obesity | Obesity clinics | Long-standing | Dealsite, 21 Jul 2017 |
| PTM | Phentermine HCl | Obesity | Obesity clinics | Long-standing | Dealsite, 21 Jul 2017 |
| Topin | Obesity-portfolio brand cited by the company (composition not disclosed in sources) | Obesity | Clinics | Long-standing | Dealsite, 21 Jul 2017 |
| Zerofat | Orlistat, co-marketed with Mothers Pharm | Obesity (fat absorption) | Clinics | 2,017 | Dealsite, 21 Jul 2017 |
| Luchion inj | Glutathione injection, widely known in Korea as a "baek-ok" (whitening) shot. Registered in Uzbekistan | Self-pay wellness / liver support | Aesthetic and wellness clinics; export | 2,012 | Dealsite, 14 Nov 2018; company news, 7 May 2026 |
| Luchion tab | Oral glutathione line extension | Wellness | Clinics and pharmacies | 2,020 | Asia Economy, 11 Nov 2020 |
| Cindella inj | Glutathione injection | Self-pay wellness | Clinics | Mid-2010s | eToday (2017) |
| Same inj | SAMe (ademetionine); licensed for depression and used in liver and pain indications | Self-pay | Clinics | 2,018 | Edaily (2018); Dealsite, 14 Nov 2018 |
| Thymosin inj | Thymosin; adjunct in cancer care | Self-pay supportive care | Integrative-oncology clinics | 2,018 | Edaily (2018) |
| Liporase inj | Lyophilized injectable; the company's main export product | Pain treatment (catalog category) | Clinics; Southeast Asia, Latin America, Middle East (Iran and Peru registrations, first shipment March 2022) | Long-standing | Company catalog; Medigate News, 12 May 2022 |
| NuPN inj | New injectable listed under pain treatment | Pain | Clinics | Recent (flagged new) | Company catalog |
| V-Bella inj | New injectable (category "other") | — | Clinics | Recent (flagged new) | Company catalog |
| NP Flu Premix inj | Ready-to-use premixed influenza antiviral injection | Influenza | Hospitals and clinics | Sep 2024 | Finance Scope, 25 Sep 2024 |
| Daehan Nupharm Acetaminophen inj | IV acetaminophen | Fever and pain | Hospitals | Recent (flagged new) | Company catalog |
| Arginine Premix inj | Premixed arginine injection | Other | Hospitals and clinics | Recent (flagged new) | Company catalog |
| Pine-S tab | Bromelain | Rhinitis / nasal congestion | Pharmacies and clinics | 2,020 | Asia Economy, 11 Nov 2020 |
| Tambutin tab | Export product, ranked among Russia's top-3 drugs (2016–2017) | — | Russian distributors | Mid-2010s | Company history page |
| Distributed vaccines and antitoxins | Pit-viper antivenom (described as the only one in Korea), varicella vaccine, live Japanese encephalitis vaccine | Prevention and envenomation | Hospitals and clinics | 2022–2023 | Medigate News, 12 May 2023 |
| Legacy reimbursed brands | Tertan tab, Amloc tab, Tarocin SR tab, NP Star tab (as listed by Morningstar) | Cardiovascular and others | Clinics | Older | Morningstar profile |
Human medical devices and aesthetics
| Product | Description | Status | Source |
|---|---|---|---|
| Derma Cindella | Device-classified dermal injectable | Flagged new | Company catalog |
| Vitamin D rapid diagnostic kit | Point-of-care test | Flagged new | Company catalog |
| HA fillers (Qgel, Flore; Plancell) | Domestic exclusive for Korea BNC fillers (2017); overseas sales of Estepharm's Plancell (2019) | Historical | eToday (2017); Dealsite, 14 May 2019 |
| Tess Lift Soft | Premium mesh-structure absorbable lifting thread, exclusive distribution | 2,018 | Dealsite, 14 Nov 2018 |
Animal health
| Product | Description | Species | Launch | Source |
|---|---|---|---|---|
| Granmectin pellet / pour-on / Plus pellet | Ivermectin-based antiparasitics | Cattle, swine; government procurement | Current | Company catalog |
| Neovitarincal powder / Gold pellet | Vitamin and mineral supplement | Cattle, swine, poultry | Current | Company catalog |
| Glu-Vitamin Health powder | Nutritional supplement | Fish | Current | Company catalog |
| Traxx inj (tulathromycin) | Treatment for bacterial respiratory disease. Generic entry followed patent expiry in H2 2019; the company said the domestic market grew from about KRW 3bn to about KRW 9bn after expiry | Cattle and swine | Approval targeted 2021; tulathromycin product launched by Q1 2022 | iNews24 (2021); Medigate News, 12 May 2022 |
| Altrenogest swine hormone | Reproductive hormone | Swine | H2 2022 (planned) | Medigate News, 12 May 2022 |
| Pamdizero | Stress reliever | Livestock | H2 2022 (planned) | Medigate News, 12 May 2022 |
| Aqua Luchion | Stress reliever | Aquaculture | H2 2022 (planned) | Medigate News, 12 May 2022 |
| Power GABA-C | Heat-stress relief | Livestock | 2,018 | Edaily (2018) |
| Chou-yu 99 (colostrum), Custan | Disease-prevention feed supplements for gut health and immunity | Livestock | 2,021 | Asia Economy (2021) |
| Cowmix, Super Cow, Neoflo | Livestock products named as key lines | Cattle and others | Long-standing | JobKorea |
| Starvac, Pigcoc for calves, Ocean Doctor | Livestock and aquaculture products | Various | Long-standing | Morningstar profile |
| DH Fuzol tab | Fluconazole for Malassezia dermatitis; company claims world-first canine fluconazole formulation | Dogs | Jun 2024 | Company history; Smart Today |
| Qvecin inj | Cefovecin sodium 80 mg/mL; long-acting injectable antibiotic (an ingredient with prior US FDA approval) for skin and urinary-tract infections; prescription veterinary drug | Dogs and cats | Jul 2026 | Company news, 1 Jul 2026 |
| D'ange | Veterinary-hospital-exclusive brand and online mall | Companion animals | May 2022 | Company history page |
Bio products
| Product | Description | Source |
|---|---|---|
| CELRENA (serum-free) | Cell-culture medium | Morningstar profile |
| BMPro / BMPro-V (serum-free) | Cell-culture media | Morningstar profile |
| ALyS505NK-EX (serum-free) | Medium for NK-cell expansion | Morningstar profile |
| Bioprocess materials | Sold since 2012; dedicated media plant since 2014 | Company history page |
Health functional foods and consumer
| Brand / product | Description | Launch | Source |
|---|---|---|---|
| DiNU Paraotics | Probiotic using cap-in-cap (capsule-in-capsule) technology, described as a Korean first | 2,021 | iNews24 (2021) |
| DiNU Polis | Brazilian green propolis plus vitamin C | 2,021 | iNews24 (2021) |
| DiNU Vitamin C 3 g (DSM ascorbic acid), DiNU Opti-MSM | Single-ingredient supplements | 2,021 | iNews24 (2021) |
| Plant-based Melatonin 5 mg, Organic Curly Kale 100 | Clean-label line | Dec 2025 | Company news, 12 Dec 2025 |
| DiNU Direct Oral Probiotics | Probiotic for oral health | Mar 2026 | Company news, 25 Mar 2026 |
| DiNU Kiup (Pokémon edition) | Children's height-growth supplement using a newly approved individually recognized ingredient (Humulus japonicus extract, HSy2); planned supply to about 22,000 pharmacies | Apr 2026 | Company news, 1 Apr 2026 |
| Dr. DiNU | Clinic-exclusive supplement brand | Jan 2023 | Company history page |
| Harker Herbals (New Zealand) | Distributed natural health brand: Manuka honey lozenges, herbal sticks; CJ home-shopping live broadcast | Apr 2026 | Company news, 16 Apr 2026 |
Financial Narrative
Basis: separate (non-consolidated) K-IFRS statements as reported to DART. FY2021–FY2025 income-statement data are from DART-derived databases (etfshopping/butler.works) and cross-checked against the company IR page for FY2025. Balance-sheet data for FY2024–FY2025 are from the company IR page (quarterly statements). Sources: company IR "재무" and "주요지표" pages (accessed October 2026); etfshopping (DART business reports, FY2016–FY2025); WISEreport (FY2025 EBITDA); Dailypharm, 13 Mar 2026 (debt and cash flow).
Income statement
Diluted EPS is not separately disclosed in the sources reviewed; no dilutive instruments were identified as outstanding. Dailypharm reported FY2021 operating profit as KRW 28.2bn (a record at the time), versus KRW 26.7bn in DART-derived data. The difference may reflect preliminary versus audited figures or a restatement.
Margins and growth (%)
Revenue CAGR FY2021–FY2025 (derived): 5.0%. Nearly all of that growth came in FY2022 (+18.8%). Revenue has been flat at about KRW 202–204bn for FY2023–FY2025.
Quarterly trajectory, Q1 2025 to Q2 2026
Source: company IR page quarterly income statements (FY2025 and FY2026). Q4 2025 net income includes a tax benefit of KRW 2.6bn; FY2025 income tax was a net benefit of KRW 0.3bn.
H1 2026 vs. H1 2025.
The company's own website headline for this release displayed the prior-year amounts (1,017억 revenue, 73억 OP, 55.8억 NI) alongside growth rates that match the H1 2026 figures. The DART-filed numbers above (KRW 110.8bn and so on) are the authoritative series (MediPharm Health News, 14 Aug 2026).
Trailing twelve months to Q2 2026 (derived). Revenue KRW 211.5bn. Operating income KRW 9.7bn (4.6% margin). Net income KRW 23.9bn, inflated by Q2 2026 financial income.
Balance sheet
Sources: company IR page (FY2024–FY2025); Dailypharm, 13 Mar 2026 (FY2023 total borrowings). No goodwill is recognized; the intangibles shown are other intangible assets. Dailypharm puts FY2025 net debt at about KRW 78bn after counting about KRW 1bn of short-term financial instruments as cash-like; FY2024 net debt was KRW 27.9bn on the same basis.
Latest interim balance sheet, 30 June 2026 (KRW bn, company IR page).
Cash flow: notes and sources
Sources: Dailypharm, 13 Mar 2026 (OCF, investing outflow, CIP acquisitions); etfshopping (dividends declared per fiscal year, paid the following April). H1 2025 operating cash flow was −KRW 4.0bn (Dealsite, 22 Aug 2025). Dailypharm (10 Jul 2026) reported a 73% decline in FY2025 operating cash flow.
Returns, leverage and efficiency ratios
Notes: - FY2025 ROE, ROA, interest coverage and asset turnover are company-reported (IR "주요지표" page). FY2024 ROE is derived as net income divided by year-end equity.
-
ROIC (derived) = operating income × (1 − 22% assumed statutory rate) ÷ (equity + net debt) at FY2025 year-end.
-
Interest coverage uses the company's definition. On total finance costs of KRW 3.0bn, operating income covers finance costs only 3.9x. Coverage fell to 4.8x in Q2 2026.
-
CCC (derived): DSO about 70 days (receivable turnover 5.2x) plus DIO about 130 days (average inventory ÷ COGS) minus DPO about 46 days.
-
Inventory turnover of 2.8x (company-reported) indicates a long inventory cycle typical of multi-SKU generic manufacturers.
Commentary on trends, inflections and drivers
Revenue. FY2022 was the inflection year. Revenue jumped 18.8% to KRW 198.0bn on strong human-drug sales: antibiotics and respiratory products during the Omicron wave, injectable growth, and the seasonal obesity business. Animal health also grew, and exports rose with Liporase registrations in Iran and Peru (Medigate News, 12 May 2022). Since then revenue has been flat at about KRW 202bn for three years even though commissions paid to CSOs nearly doubled. Dailypharm (10 Jul 2026) and Dealsite (21 Aug 2025) both argue that the CSO model is buying prescriptions at rising cost without expanding the top line. H1 2026 shows the first meaningful growth in three years (+8.9%), led by all human sub-segments and a higher animal-health share.
Gross margin. The long-run decline from 55.7% (FY2016) to 45.6% (FY2025) and then to 40.9% in Q2 2026 reflects several factors:
-
mix shift away from high-margin self-pay injectables;
-
more distributed and in-licensed products;
-
raw-material cost inflation; and
-
in 2026, cost pressure before the new plant contributes volume.
Management cited cost-of-goods increases in Q1 2026 (WISEreport). Q4 2025 to Q2 2026 gross margins of 41% to 43% are the lowest in the available record.
Operating margin. Margin fell from 16.0% (FY2021) to 5.8% (FY2025) as SG&A rose from KRW 57.3bn to KRW 80.5bn (derived), crossing KRW 80bn for the first time in FY2025 (Dailypharm, 10 Jul 2026). The main drivers were CSO commissions and R&D: research spending rose from KRW 6.3bn (FY2022) to KRW 8.7bn (FY2023), and H1 2025 spending approached the full FY2024 level (IB Tomato, 3 Sep 2025). FY2023 was also hit by the KRW 7.1bn tax assessment, recognized partly through operating results; Dailypharm attributes the 32% FY2023 operating-profit decline to the extra tax and higher R&D.
Net income quality. Reported net income has repeatedly been distorted by one-off items:
-
tax charges: FY2014 KRW 2.8bn, FY2017 KRW 17.2bn, FY2023 KRW 7.1bn;
-
litigation: a provision linked to Lightpharmtech, then about KRW 9bn reversed in Q1 2022;
-
financial income: KRW 13.0bn in Q2 2026, most plausibly valuation or disposal gains on the listed-equity portfolio. This attribution is not confirmed in the sources reviewed; Dealsite (22 Aug 2025) reported the SK hynix position up 169% versus cost.
Operating income is the better measure of core earning power. On that basis TTM earnings are about KRW 9.7bn, roughly one-third of the FY2022 peak.
Balance sheet and cash flow. The Hyangnam Plant 2 investment changed the balance sheet:
-
PP&E rose from KRW 85.0bn to KRW 133.3bn in FY2025 and KRW 138.6bn by June 2026.
-
Total borrowings rose from KRW 36.0bn (FY2023) to KRW 105.6bn (June 2026).
-
FY2025 free cash flow was about −KRW 42.6bn.
-
Operating cash flow was only KRW 5.0bn, as working capital (inventory) absorbed cash and profits fell.
Short-term borrowings plus current long-term debt of KRW 47.5bn exceed cash of KRW 15.3bn about three times over. That makes rollover of bank lines a structural need; the board approved borrowing extensions in January 2024 and January 2025. Leverage is still manageable relative to equity of KRW 149bn, and the listed-equity portfolio and the Caspian Sunrise stake are sources of liquidity that could be sold. IB Tomato (3 Sep 2025) reports a further KRW 15bn of production-capacity and building investment plus KRW 4.5bn of facility maintenance planned through 2027.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Representative products |
|---|---|---|
Human pharmaceuticals (인체의약품) | Domestic prescription (reimbursed) drugs, obesity drugs, self-pay well-being injectables, OTC, medical devices, distributed vaccines | Rapiduo, Newtozet, Migbos, Pentin/Festin, Luchion, Liporase, NuPN, NP Flu Premix |
Animal pharmaceuticals (동물의약품) | Livestock, aquaculture and apiculture drugs; feed supplements; companion-animal medicines; government-procurement products | Granmectin, Neovitarincal, Cowmix, Neoflo, DH Fuzol, Qvecin |
Overseas business division (해외사업부) | Exports of human (and some veterinary) finished products | Liporase, Luchion inj, Tambutin |
Revenue by Segment (%)
| Segment (% of revenue) | 9M2022 | Q1 2026 | Q2 2026 |
|---|---|---|---|
Human pharmaceuticals | — | 56.2 | 56 |
Animal pharmaceuticals | — | 26.3 | 29 |
Overseas business | 6.8 | 8.1 | 8 |
Contract manufacturing and other | — | 9.5 | 7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment (KRW Bn, Derived) Overview
| Segment (KRW Bn, derived) | H1 2026 |
|---|---|
Human pharmaceuticals | 62.0 |
Animal pharmaceuticals | 32.1 |
Overseas business | 8.9 |
Contract manufacturing and other | 7.8 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 166.6 | 198.0 | 204.2 | 202.2 | 202.4 |
Gross profit (KRW Bn) | 84.0 | 90.5 | 94.0 | 96.9 | 92.3 |
SG&A (KRW Bn, derived = GP − OP) | 57.3 | 62.9 | 75.2 | 78.2 | 80.5 |
Operating income (KRW Bn) | 26.7 | 27.6 | 18.8 | 18.7 | 11.7 |
EBITDA (KRW Bn) | — | — | — | — | 16.0 |
Pre-tax income (KRW Bn) | — | — | — | — | 15.0 |
Net income (KRW Bn) | 15.7 | 24.3 | 12.5 | 15.5 | 15.3 |
EPS basic (KRW) | 1,118 | 1,733 | 894 | 1,102 | 1,087 |
Dividend per share (KRW) | 80 | 100 | 100 | 100 | 100 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth (%) | 11.6 | 18.8 | 3.2 | -1.0 | 0.1 |
Gross margin (%) | 50.4 | 45.7 | 46.0 | 47.9 | 45.6 |
Operating margin (%) | 16.0 | 13.9 | 9.2 | 9.2 | 5.8 |
EBITDA margin (%) | — | — | — | — | 7.9 |
Net margin (%) | 9.4 | 12.3 | 6.1 | 7.7 | 7.5 |
SG&A / revenue (%, derived) | 34.4 | 31.8 | 36.8 | 38.7 | 39.8 |
Income Statement and Margin Analysis (%)
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 51.9 | 49.9 | 48.9 | 51.8 | 54.8 | 56.0 |
Gross margin (%) | 47.6 | 47.7 | 45.8 | 41.4 | 42.5 | 40.9 |
Operating income (KRW Bn) | 4.2 | 3.1 | 2.1 | 2.3 | 3.1 | 2.2 |
Operating margin (%) | 8.2 | 6.1 | 4.3 | 4.5 | 5.7 | 3.8 |
Finance income (KRW Bn) | 0.6 | 1.1 | 1.5 | 2.9 | 2.0 | 13.0 |
Net income (KRW Bn) | 2.6 | 3.0 | 2.6 | 7.1 | 3.0 | 11.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis
| Metric | H1 2025 (KRW Bn) | H1 2026 (KRW Bn) | Change |
|---|---|---|---|
Revenue | 101.7 | 110.8 | +8.9% |
Operating income | 7.3 | 5.3 | −27.6% |
Net income | 5.6 | 14.3 | +155% |
Balance Sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total assets (KRW Bn) | — | 221.3 | 270.7 |
Cash and equivalents (KRW Bn) | — | 29.7 | 20.0 |
Total borrowings (KRW Bn) | 36.0 | 58.5 | 98.0 |
Short-term borrowings (KRW Bn) | — | 39.7 | 43.9 |
Long-term borrowings (KRW Bn) | — | 18.8 | 54.1 |
Net debt (KRW Bn, derived) | — | 28.8 | 78.0 |
Total liabilities (KRW Bn) | — | 95.8 | 130.8 |
Shareholders' equity (KRW Bn) | — | 125.4 | 139.9 |
Property, plant and equipment (KRW Bn) | — | 85.0 | 133.3 |
Goodwill and intangibles (KRW Bn) | — | 1.1 | 1.6 |
Inventories (KRW Bn) | — | 37.2 | 41.1 |
Trade and other receivables (KRW Bn) | — | 39.7 | 38.4 |
Working capital (KRW Bn, derived) | — | 43.5 | 42.2 |
Financial Analysis — Total assets
| Item | Value |
|---|---|
Total assets | 281.4 |
Cash and equivalents | 15.3 |
Short-term borrowings | 46.0 |
Current portion of long-term debt | 1.5 |
Long-term borrowings | 58.1 |
Total borrowings | 105.6 |
Net debt (derived) | 90.4 |
PP&E | 138.6 |
Total liabilities | 132.4 |
Equity | 149.0 |
Liabilities-to-equity ratio | 88.8% |
Current ratio | 176.7% |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | — | — | — | 18.9 | 5.0 |
Capex: construction-in-progress acquisitions (KRW Bn) | — | — | — | — | 47.6 |
Investing cash outflow (KRW Bn) | — | — | — | — | 52.1 |
Free cash flow (KRW Bn, derived = OCF − capex) | — | — | — | — | -42.6 |
Dividends paid in year (KRW Bn) | 0 | 1.12 | 1.40 | 1.40 | 1.40 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%) and Financial Ratios (x)
| Metric | FY2024 | FY2025 |
|---|---|---|
ROE (%) | 12.3 | 10.9 |
ROA (%) | — | 5.6 |
ROIC (%, derived) | — | 4.2 |
Current ratio (%) | 160.5 | 157.9 |
Borrowings / equity (%) | 46.6 | 70.0 |
Liabilities / equity (%) | 76.4 | 93.5 |
Net debt / EBITDA (x, derived) | — | 4.9 |
Interest coverage (x) | — | 7.0 |
Asset turnover (x) | — | 0.8 |
Cash conversion cycle (days, derived) | — | 154 |
Revenue by Region (%)
| Metric | 9M2022 | Q1 2026 | Q2 2026 |
|---|---|---|---|
Overseas share of revenue (%) | 6.8 | 8.1 | 8 |
Domestic share of revenue (%, derived) | 93.2 | 91.9 | 92 |
Region / Country Details
| Region / country | Evidence | Products |
|---|---|---|
Southeast Asia | Described as the core export market for Liporase (2022) | Liporase |
Latin America (Peru) | Registration completed; first shipment March 2022 | Liporase |
Middle East (Iran) | Registration completed (2022) | Liporase |
Russia | Tambutin among Russia's top-3 drugs in 2016–2017 | Tambutin |
Uzbekistan / CIS | Products including Luchion inj registered with Uzbek regulators; exhibited at Tashkent medical expo (28–30 Apr 2026) | Luchion inj and others |
United States | US customs records show 61 import shipments to the company since 2007, mostly raw materials and feed ingredients (HS 12, 23, 29, 39). These are inbound purchases, not export sales | Panjiva |
Capital Markets
| Item | Value | Source |
|---|---|---|
Last close | KRW 5,440 (20 Oct 2026) | etfshopping |
Market capitalization | KRW 78.1bn | etfshopping |
52-week range | KRW 5,090 to 7,510 (etfshopping, Oct 2026). Earlier snapshots showed KRW 5,030 to 7,900 (TipRanks, stockhub), reflecting different windows | Sources conflict; both shown |
Return, 1 month | −1.1% | etfshopping |
Return, 6 months | −23.9% | etfshopping |
Return, 1 year | −18.3% | etfshopping |
Return, 3 years and 5 years | Reference points: market cap KRW 157.2bn in Aug 2022, KRW 123.2bn in Jan 2023, KRW 107.5bn in Jul 2025 and KRW 78.1bn in Oct 2026, implying a decline of about 50% since Aug 2022 (derived) | Dailypharm; etfshopping |
All-time market-cap peak | KRW 271.3bn (28 Feb 2017) | Dailypharm, 6 Jan 2023 |
Average daily volume | About 30,000 to 32,000 shares (3-month average about 32.2k) | TipRanks |
Beta | 0.13 (TipRanks) | TipRanks |
Buyback authorizations | None in FY2016–FY2025; no buyback or cancellation announced in the last 12 months. Treasury shares about 2.23% | etfshopping; butler.works |
Credit ratings (Moody's, S&P, Fitch) | None. The company has no public bonds; domestic bond and CP ratings are blank on WISEreport | WISEreport |
Debt maturity profile (30 June 2026) | Due within 12 months: KRW 47.5bn (short-term borrowings KRW 46.0bn plus current long-term debt KRW 1.5bn). Long-term borrowings: KRW 58.1bn. Detailed maturity ladder not publicly disclosed in the sources reviewed | Company IR page |
Valuation Multiples
| Multiple | Daehan Nupharm | Basis |
|---|---|---|
P/E (FY2025 EPS of KRW 1,087) | 5.0x | etfshopping |
P/E (TTM EPS of about KRW 1,667, derived) | 3.3x | Inflated by Q2 2026 financial income |
P/B (FY2025 BPS of KRW 9,971) | 0.55x | WISEreport BPS |
P/B (June 2026 equity, derived) | about 0.51x | Company IR |
EV / EBITDA (FY2025 EBITDA of KRW 16.0bn; EV KRW 168.4bn at June 2026 net debt, derived) | about 10.5x | WISEreport showed 9.07x at an earlier price and on year-end debt |
EV / sales (TTM, derived) | about 0.80x | Company IR |
Dividend yield | 1.85% | etfshopping |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (KRW) | 80 | 100 | 100 | 100 | 100 |
Total dividends (KRW Bn) | 1.12 | 1.40 | 1.40 | 1.40 | 1.40 |
Payout ratio (%) | 7.2 | 5.8 | 11.2 | 9.1 | 9 |
Dividend yield at record date (%) | 0.7 | 1.1 | 1.1 | 1.4 | — |
Analyst Conclusions
Management guidance
No quantitative revenue or earnings guidance is disclosed. Qualitative guidance:
-
Complete Plant 2 qualification and receive GMP approval (target August to November 2026).
-
Start the injectable lines in early 2027.
-
Strengthen the sales organization to convert higher 2027 output and new products into revenue (Newspim, 14 May 2026).
Consensus expectations
None. There is no sell-side coverage.
Bull case
-
Capacity-led re-acceleration. H1 2026 revenue grew 8.9% before Plant 2 contributes. If the new lines add own-product volume, exports (Liporase, Luchion, Central Asia) and contract manufacturing from 2027, revenue could break out of the KRW 200bn range, and operating leverage on an SG&A base of about KRW 80bn could restore 10%-plus margins.
-
Asset backing. At about 0.5x book, with a 10.8% Caspian Sunrise stake and a listed-equity portfolio (Q2 2026 finance income KRW 13.0bn), the market value of KRW 78bn is substantially covered by tangible and financial assets. Monetizing them could cut net debt of about KRW 90bn quickly.
-
Optionality in obesity and pet health. Participation in a 4-week long-acting obesity injectable consortium, a Phase 3 veterinary cell therapy (Nustem), and new companion-animal antibiotics (Qvecin) and antifungals (DH Fuzol) add low-cost upside that the current multiples do not price.
Bear case
-
Structural margin decline. Gross margin fell from 47.6% to 40.9% between Q1 2025 and Q2 2026, and operating margin to 3.8%. CSO commissions above KRW 40bn suggest that growth is being bought. Adding Plant 2 depreciation to a stagnant product base could push operating profit close to zero in 2027.
-
Balance-sheet strain. Borrowings nearly tripled from KRW 36bn (FY2023) to KRW 106bn (June 2026), with about 45% short-term. FY2025 operating cash flow of KRW 5bn did not cover dividends plus maintenance capex. Further capex of about KRW 19.5bn is planned through 2027.
-
Governance and earnings quality. Recurring tax assessments, net income propped up by securities gains, two amendments of the FY2025 annual filings, a three-person board dominated by the founding family, and succession incentives that may not favor a higher share price before a share gift.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Mid-Nov 2026 | Q3 2026 report: gross-margin trend, operating cash flow, borrowings, finance income |
| Aug–Nov 2026 (target) | MFDS GMP approval for Plant 2 |
| Early 2027 | Start of the injectable lines; product-transfer progress; first exports and contract volumes from Plant 2 |
| Mar 2027 | FY2026 results and dividend; AGM with all director and auditor terms expiring (board-renewal and independence signal) |
| Ongoing | Any share gift from the Chairman to the CEO; insider and large-holding filings; changes to the CEO's share pledges |
| Ongoing | Sales of non-core assets (Caspian Sunrise, listed equities) and use of proceeds |
| Ongoing | Progress of the obesity injectable consortium; Nustem Phase 3 readout; new improved-drug approvals (obesity, hypertension, GERD) |
| Ongoing | CSO commission trajectory and any regulatory action on the CSO channel |
Analyst verdict
Daehan Nupharm is a profitable but stagnating Korean specialty pharmaceutical company at an inflection point it has created itself. For three years the core franchise has produced about KRW 202bn of revenue on steadily falling margins. Operating profit fell from KRW 27.6bn in FY2022 to KRW 11.7bn in FY2025, and further to a TTM figure of about KRW 9.7bn. The causes are structural rather than cyclical: a generic-heavy reimbursed portfolio that depends on rising CSO commissions, a mature appetite-suppressant franchise facing the GLP-1 era, and cost-of-goods pressure that has driven gross margin to the low 40s.
Against this background, management has made the largest bet in the company's history: a roughly KRW 81bn GMP plant designed to EU-GMP Annex 1 standards. The plant doubles solid-dose capacity and adds aseptic lyophilized lines. It is a credible industrial asset. But it was financed largely with debt, net debt is now about KRW 90bn, and its return depends on commercial execution that the company has not yet shown: exports at only about 8% of sales, a thin R&D budget, and no proprietary lead product.
The valuation already reflects much of this skepticism. The shares trade at about 0.5x book, 5x trailing FY2025 earnings and a 1.9% yield, with substantial non-core assets (Caspian Sunrise, listed equities) that could be sold. Governance is the swing factor. Family control at 40.5%, an unresolved succession, pledged CEO shares, a 9% payout and repeated tax and disclosure issues all explain the persistent discount.
On balance, the profile is a deep-value, execution-dependent special situation, not a quality compounder. A re-rating would need three things: GMP approval and visible utilization of Plant 2 in 2027; stabilization of gross margin at 45% or above; and capital-allocation discipline, meaning debt reduction funded by non-core asset sales and a clearer shareholder-return policy. Until those are visible, downside is cushioned by assets, but earnings momentum and governance remain the dominant risks.
APPENDIX — SOURCE LIST AND DATA NOTES
Company sources.
-
dhnp.co.kr: home and updates; history (발자취); factory (공장); R&D pipeline; IR financial statements (재무) and ratios (주요지표) covering FY2024 to Q2 2026; governance overview, board (이사회) and shareholder (주주정보) pages; product catalogs (human and veterinary).
-
Company press releases (2025–2026) on Q1 2026, H1 2026, the ESG rating, DiNU launches, the Tashkent expo and Qvecin.
Regulatory filings (via index and DART-derived databases).
-
DART filing index (IRGO), Nov 2025 to Aug 2026.
-
FY2021–FY2025 business reports (employees, shareholders, executive pay, investees) via etfshopping.com.
-
DART-derived financials via etfshopping.com and butler.works.
-
WISEreport company page (June/July 2026 snapshot, as surfaced in search).
Press.
-
Dailypharm (2022–2026): succession, tax assessments, borrowings, plant, commissions.
-
Dealsite (2017–2025): CSO commissions, equity portfolio, share pledges, Daewoong consortium.
-
IB Tomato (2023, 2025): CEO profile and capex/R&D.
-
Medigate News (2021–2023): litigation, Q1 results, CEO appointment, vaccines.
-
MediPharm Health News (Aug 2025, Aug 2026).
-
Newspim (May 2026); Asia Economy (2020–2021); iNews24 (2021); Edaily (2018, 2022); eToday (2017; Jul 2026 on veterinary GMP reform); KPA News (Feb and Oct 2026); Biotimes; Finance Scope; Smart Today (May 2024); Economist Korea (Jun 2026).
Third-party profiles. Morningstar; TipRanks; PitchBook; TheVC; Panjiva; JobKorea; Jasoseol; Judal; stockhub.
Peer data. butler.works and etfshopping (Huons, Dai Han Pharm, Choongang Vaccine, Eagle Vet); Medigate News and Fintech Times (Huons group FY2025).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Position | Term expires | Background | Age | Source |
|---|---|---|---|---|---|
Lee Wan-jin (이완진) | Inside director; Chairman, overall management | 18 Mar 2027 | Founder; former Representative Director (sole CEO 2020–2022; co-CEO before 2020) | About 75 (reported as 74 in Jul 2025) | Company board page; Dailypharm |
Lee Won-seok (이원석) | Inside director; Representative Director and President, head of management | 18 Mar 2027 | Born 1977. Joined 2004 (some sources say 2005). Worked in the overseas business, finance and management teams; Executive VP of the management division; inside director since 2018; sole CEO since 2 Jan 2023. Created a "Future Business Division" to drive cross-unit synergy | 49 | Medigate News, 4 Jan 2023; company board page |
Jung In-kyung (정인경) | Outside (independent) director | 21 Mar 2027 | Professor of endocrinology and metabolism, Kyung Hee University Hospital at Gangdong; head of its clinical trial center | — | Company board page |
Kwon Oh-kyung (권오경) | Full-time statutory auditor | 20 Mar 2027 | Former dean of Seoul National University College of Veterinary Medicine; former professor of veterinary orthopedics; former president of the Korean Society of Veterinary Surgery and the Korean Society of Veterinary Clinics | — | Company board page |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Background | Source |
|---|---|---|---|
Gil Young-sik (길영식) | Managing Director; Head of Central Research Institute (appointed H1 2025) | Head of research at Sam-A Pharm from June 2020 | Dailypharm, 22 Jul 2025 |
Song Young-jun (송영준) | Executive VP; head of synthetic-drug R&D | — | Dailypharm, 22 Jul 2025 |
Kwon Young-do (권영도) | Head of Bio Research Institute (biologics R&D) | — | Dailypharm, 22 Jul 2025 |
Park Jung-tae (박정태) | Director; head of scientific/academic development (pharmaceutical development) | Newly recruited in 2025 | Dailypharm, 22 Jul 2025 |
“—” = not publicly disclosed.
Executive Leadership Team (Annual)
| Name | Title | Total FY2025 compensation (KRW Bn) |
|---|---|---|
Lee Wan-jin | Chairman | 0.90 |
Lee Won-seok | CEO | 0.52 |
Average per director/auditor (4 persons) | — | 0.37 |
Board & Management Changes
| Date | Change |
|---|---|
31 Jan 2020 | Co-CEO structure (Lee Young-seop and Lee Wan-jin) replaced by Lee Wan-jin as sole CEO |
2 Jan 2023 | Lee Won-seok appointed sole Representative Director and President; founder steps down as CEO but remains Chairman |
18 Mar 2024 | Board resolution on reappointing the CEO and on dismissing and appointing the company's registered manager (지배인) |
H1 2025 | Gil Young-sik (R&D) and Park Jung-tae (scientific/academic development) recruited |
Major Shareholders
| Holder | Relationship | Stake (%) |
|---|---|---|
Lee Wan-jin | Largest shareholder (founder) | 26.53 |
Lee Won-seok | Son (CEO) | 7.92 |
Choi Sung-sook | Spouse | 2.46 |
Avent Korea Co., Ltd. | Related company (effectively controlled by daughter Lee Ji-min) | 1.97 |
Lee Ji-min | Daughter | 1.39 |
Other family members (3) | Daughter-in-law and grandchildren | 0.21 |
Total largest shareholder and related parties | — | 40.50 |
Treasury shares | Company | about 2.23 |
Minority shareholders (10,916 holders) | — | 56.87 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Overlap | Comparative scale (FY2025 unless noted) | Source |
|---|---|---|---|---|
Self-pay injectables / wellness | Huons (243070) | Injectables, well-being and aesthetic injectables, exports | Consolidated revenue KRW 620.8bn; operating profit KRW 45.6bn | Medigate News, 14 Feb 2026 |
Aesthetics / injectables | Humedix (Huons group) | HA fillers, injectables | Revenue KRW 170.1bn; operating profit KRW 42.3bn | Fintech Times, Feb 2026 |
Hospital injectables / fluids | Dai Han Pharm (023910) | Hospital injectables (ampoules and vials) | Revenue KRW 208.6bn; operating profit KRW 31.2bn | butler.works |
Obesity drugs | Daewoong Pharmaceutical | Obesity (also a consortium partner) | Not compiled in this research | Dealsite, 15 May 2025 |
Obesity drugs (incretins) | Novo Nordisk (Wegovy), Eli Lilly (Mounjaro) | GLP-1 and GIP/GLP-1 therapies displacing older oral appetite suppressants | Global scale; Lilly's Q1 2026 Mounjaro sales were USD 8.66bn | Economist Korea, Jun 2026 |
Small/mid generic pharma | Korea Pharma, Dongkoo Bio & Pharma, Shinpoong Pharm, BC World Pharm | Generics and clinic-channel prescriptions | Not compiled in this research | TheVC "similar companies" list |
Animal health (vaccines) | Choongang Vaccine Laboratories (072020) | Swine, poultry and companion-animal biologics | Revenue KRW 49.1bn; operating profit KRW 6.5bn | butler.works |
Animal health (drugs, exports) | Eagle Vet (044960) | Livestock drugs, feed additives, companion-animal products, EU-GMP veterinary plant | Revenue KRW 43.3bn; operating profit KRW 4.3bn | butler.works |
Animal health (other domestic) | Woojin B&G, Daesung Microbiological Labs, Komipharm, Jeil Bio | Livestock biologics and drugs | Not compiled in this research | — |
Animal health (multinationals) | Zoetis, MSD Animal Health, Boehringer Ingelheim Animal Health, Elanco (Korean subsidiaries) | Antiparasitics, antibiotics, companion-animal drugs. Zoetis's Convenia is the reference cefovecin product that Qvecin competes with | Global scale | — |
Health functional foods | Large domestic HFF players (for example, Korea Ginseng Corp., Chong Kun Dang Health) | Probiotics, vitamins, children's growth supplements | Not compiled in this research | — |
Peer Comparison FY2025
| Metric | Daehan Nupharm | Huons | Dai Han Pharm | Choongang Vaccine | Eagle Vet |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 202.4 | 620.8 | 208.6 | 49.1 | 43.3 |
Revenue growth (%) | 0.1 | 5.2 | 2.2 | 7.6 | 3.9 |
Operating margin (%) | 5.8 | 7.3 | 15.0 | 13.2 | 9.9 |
Market cap (KRW Bn) | 78.1 | 267.1 | 159.0 | 86.2 | 38.8 |
P/E (x) | 5.0 | 14.2 | 5.8 | 10.8 | 7.1 |
P/B (x) | 0.56 | 0.73 | 0.52 | 0.80 | 0.71 |
R&D / revenue (%) | 3.8 | — | — | — | — |



